Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,changeToLiabilities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,totalCashflowsFromInvestingActivities,otherCashflowsFromFinancingActivities,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,epsCurrentYear,market,shortName,exchange,marketState,priceHint,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,exchangeDataDelayedBy,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Apr 14, 2021) 4","Short Ratio (Apr 14, 2021) 4","Short % of Float (Apr 14, 2021) 4","Short % of Shares Outstanding (Apr 14, 2021) 4","Shares Short (prior month Mar 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,GTHX,177351000.0,42058300,15419000,,-24868000,,-25347000,25215000,16546000,-24088000,-24088000,,-756000,,,,479000,16546000,40634000,0,-780000,,-25347000,-25347000,613462000.0,51201000.0,177351000.0,2397000.0,228552000.0,4000.0,63000.0,-436107000.0,-8000.0,1652000.0,207306000.0,23443000.0,10508000.0,216392000.0,237000.0,19893000.0,3572000.0,-12663000.0,472000.0,1518000.0,472000.0,-31036000.0,-31508000.0,120000.0,-237000.0,4837000.0,,,,192949000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,15.32,1630526403,0.19999981,15.21,15.56,15.09,859615,-4.2674093,4.653,16.12,-0.80000114,-0.04962786,20.793333,-5.4733334,-0.2632254,644333120,-4.402299,3.2924995,15,America/New_York,EDT,False,False,USD,-3.59,us_market,"G1 Therapeutics, Inc.",NMS,PREPRE,2,0.0,1630530325,15.32,0.0,1.3227501,15.09 - 15.56,15.12,0.0,0.0,8,18,finmb_141112421,NasdaqGS,"G1 Therapeutics, Inc.",USD,1121181,835585,4.5099993,0.4172062,10.81 - 37.069,-21.749,-0.58671665,10.81,37.069,1620244800,1620244800,0,1620244800,-2.62,-3.48,-14400000,2.33,,,37.07,10.81,16.12,20.79,1.12M,835.59k,42.06M,,35.05M,10.07%,73.96%,6.96M,6.39,16.68%,16.57%,7.66M,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",-219.18%,-213.04%,-23.49%,-45.86%,45.28M,1.20,,45.28M,-95.89M,-99.25M,-2.62,,207.31M,4.94,28.75M,16.21,9.23,4.65,-83.74M,-45.36M,Value,27709,Healthcare,122,8,2,"G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.",Research Triangle Park,919 213 9835,NC,8,1577750400,1619740800,7,United States,http://www.g1therapeutics.com,86400,8,700 Park Offices Drive,919 741 5830,Biotechnology,Suite 200
t-1,GTHX,197472000.0,42058300,17932000,,-10743000,,-11674000,18412000,26599000,-9745000,-9745000,,-757000,,,,931000,26599000,36344000,0,-998000,,-11674000,-11674000,608236000.0,60760000.0,197472000.0,14031000.0,258232000.0,4000.0,63000.0,-410760000.0,-8000.0,1755000.0,238342000.0,32959000.0,10883000.0,245594000.0,,19673000.0,2309000.0,13524000.0,284000.0,-3820000.0,379000.0,4075000.0,3639000.0,145000.0,-237000.0,5201000.0,152000.0,-95000.0,,212635000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,15.32,1630526403,0.19999981,15.21,15.56,15.09,859615,-4.2674093,4.653,16.12,-0.80000114,-0.04962786,20.793333,-5.4733334,-0.2632254,644333120,-4.402299,3.2924995,15,America/New_York,EDT,False,False,USD,-3.59,us_market,"G1 Therapeutics, Inc.",NMS,PREPRE,2,0.0,1630530325,15.32,0.0,1.3227501,15.09 - 15.56,15.12,0.0,0.0,8,18,finmb_141112421,NasdaqGS,"G1 Therapeutics, Inc.",USD,1121181,835585,4.5099993,0.4172062,10.81 - 37.069,-21.749,-0.58671665,10.81,37.069,1620244800,1620244800,0,1620244800,-2.62,-3.48,-14400000,2.33,,,37.07,10.81,16.12,20.79,1.12M,835.59k,42.06M,,35.05M,10.07%,73.96%,6.96M,6.39,16.68%,16.57%,7.66M,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",-219.18%,-213.04%,-23.49%,-45.86%,45.28M,1.20,,45.28M,-95.89M,-99.25M,-2.62,,207.31M,4.94,28.75M,16.21,9.23,4.65,-83.74M,-45.36M,Value,27709,Healthcare,122,8,2,"G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.",Research Triangle Park,919 213 9835,NC,8,1577750400,1619740800,7,United States,http://www.g1therapeutics.com,86400,8,700 Park Offices Drive,919 741 5830,Biotechnology,Suite 200
t-2,GTHX,203845000.0,42058300,1834000,,-31210000,,-31210000,14431000,-14557000,-30822000,-30822000,,-265000,,,,0,2140000,32962000,16697000,-388000,,-31210000,-31210000,602935000.0,49752000.0,203845000.0,,253597000.0,4000.0,63000.0,-399086000.0,-8000.0,1798000.0,234267000.0,21924000.0,11708000.0,240091000.0,,19453000.0,2816000.0,-1860000.0,20713000.0,358000.0,1238000.0,-8135000.0,-28848000.0,158000.0,-237000.0,3618000.0,152000.0,-525000.0,20000000.0,218167000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,15.32,1630526403,0.19999981,15.21,15.56,15.09,859615,-4.2674093,4.653,16.12,-0.80000114,-0.04962786,20.793333,-5.4733334,-0.2632254,644333120,-4.402299,3.2924995,15,America/New_York,EDT,False,False,USD,-3.59,us_market,"G1 Therapeutics, Inc.",NMS,PREPRE,2,0.0,1630530325,15.32,0.0,1.3227501,15.09 - 15.56,15.12,0.0,0.0,8,18,finmb_141112421,NasdaqGS,"G1 Therapeutics, Inc.",USD,1121181,835585,4.5099993,0.4172062,10.81 - 37.069,-21.749,-0.58671665,10.81,37.069,1620244800,1620244800,0,1620244800,-2.62,-3.48,-14400000,2.33,,,37.07,10.81,16.12,20.79,1.12M,835.59k,42.06M,,35.05M,10.07%,73.96%,6.96M,6.39,16.68%,16.57%,7.66M,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",-219.18%,-213.04%,-23.49%,-45.86%,45.28M,1.20,,45.28M,-95.89M,-99.25M,-2.62,,207.31M,4.94,28.75M,16.21,9.23,4.65,-83.74M,-45.36M,Value,27709,Healthcare,122,8,2,"G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.",Research Triangle Park,919 213 9835,NC,8,1577750400,1619740800,7,United States,http://www.g1therapeutics.com,86400,8,700 Park Offices Drive,919 741 5830,Biotechnology,Suite 200
t-3,GTHX,229450000.0,42058300,1800000,,-31023000,,-31023000,11387000,-18634000,-31821000,-31821000,,-265000,,,,0,0,31821000,18634000,798000,,-31023000,-31023000,597330000.0,27064000.0,229450000.0,,256514000.0,4000.0,63000.0,-367876000.0,-8000.0,437000.0,242402000.0,18448000.0,12488000.0,243589000.0,,,4703000.0,992000.0,219000.0,-1888000.0,219000.0,-26806000.0,-27025000.0,159000.0,-237000.0,4735000.0,152000.0,-525000.0,20000000.0,225141000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,15.32,1630526403,0.19999981,15.21,15.56,15.09,859615,-4.2674093,4.653,16.12,-0.80000114,-0.04962786,20.793333,-5.4733334,-0.2632254,644333120,-4.402299,3.2924995,15,America/New_York,EDT,False,False,USD,-3.59,us_market,"G1 Therapeutics, Inc.",NMS,PREPRE,2,0.0,1630530325,15.32,0.0,1.3227501,15.09 - 15.56,15.12,0.0,0.0,8,18,finmb_141112421,NasdaqGS,"G1 Therapeutics, Inc.",USD,1121181,835585,4.5099993,0.4172062,10.81 - 37.069,-21.749,-0.58671665,10.81,37.069,1620244800,1620244800,0,1620244800,-2.62,-3.48,-14400000,2.33,,,37.07,10.81,16.12,20.79,1.12M,835.59k,42.06M,,35.05M,10.07%,73.96%,6.96M,6.39,16.68%,16.57%,7.66M,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",-219.18%,-213.04%,-23.49%,-45.86%,45.28M,1.20,,45.28M,-95.89M,-99.25M,-2.62,,207.31M,4.94,28.75M,16.21,9.23,4.65,-83.74M,-45.36M,Value,27709,Healthcare,122,8,2,"G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.",Research Triangle Park,919 213 9835,NC,8,1577750400,1619740800,7,United States,http://www.g1therapeutics.com,86400,8,700 Park Offices Drive,919 741 5830,Biotechnology,Suite 200
